This week's FierceBiotech is brought to you by Trianni.

Trianni has developed transgenic immunoglobulin mice capable of expressing the full human antibody repertoire.

Trouble viewing? Click here.

Monoclonal antibodies (mAbs) produced from transgenic mice are now established as the industry standard for biologic drug discovery and human therapy. The most favorable transgenic mice have the ability to produce a diverse repertoire of fully human monoclonal antibodies in the absence of any contaminating mouse antibody sequences; few existing or envisioned transgenic mouse platforms meet these criteria. The Trianni Mouse is the only one to do so in a single organism.

Because of The Trianni Mouse’s ability to produce high titers of highly diverse, antigen-specific leads, this particular transgenic mouse is the optimal source for producing human monoclonal antibodies with high affinity and specificity against a broad spectrum of human antigens.

Request more information about all of TRIANNI's platforms, including the newest platform offerings with enhanced features for better human antibody discovery.
 
Learn More
Attending BIO Convention in Boston? Schedule a 1:1 meeting with TRIANNI.
Copyright © 2018 Trianni, All rights reserved.

Want to reach 150,000+ FierceBiotech subscribers with your own message?
Contact aalcover@fiercemarkets.com or call 202-824-5074.



About this email: In order to receive FierceBiotech for free, we ask that you accept an occasional email promotion from our sponsors. We carefully screen each promotion and never sell or give away your personal information. If you do not want to receive these messages, you can unsubscribe entirely from FierceBiotech.
Click here to unsubscribe.

FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400 
Washington, DC 20036

.